Showing 14,481 - 14,500 results of 55,503 for search '(( a ((mean decrease) OR (linear decrease)) ) OR ( a ((largest decrease) OR (greater decrease)) ))', query time: 0.83s Refine Results
  1. 14481
  2. 14482
  3. 14483

    Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021 by Stein Emil, Vollset

    Published 2024
    “…Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. …”
    Get full text
    Get full text
    Get full text
  4. 14484

    Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021 by Stein Emil, Vollset

    Published 2024
    “…Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. …”
    Get full text
    Get full text
    Get full text
    article
  5. 14485
  6. 14486

    Transporter inhibitor MK571 inhibited the generation and excretion of demethoxycurcumin-<i>O</i>-glucuronides in HeLa1A1 cells. by Beibei Zhang (509356)

    Published 2019
    “…<p>(A) MK571 (5 and 20 μM) inhibited the excretion of demethoxycurcumin-<i>O</i>-glucuronides (G1) in extracellular medium; (B) Inhibitory effects of MK571 (5 and 20 μM) on the excretion of demethoxycurcumin-<i>O</i>-glucuronides (G2) in extracellular solution; (C) MK571 (5 and 20 μM) decreased the efflux excretion rates of G1 and G2; (D) MK571 (5 and 20 μM) evaluated the intracellular levels of G1 and G2; (E) MK571 (5 and 20 μM) reduced the overall formation (<i>f</i><sub>met</sub>) of G1 and G2 in HeLa1A1 cell; The concentration of demethoxycurcumin was 4 μM. …”
  7. 14487
  8. 14488
  9. 14489
  10. 14490

    Effects of ESE-16 on ROS and lysosomal activity in MDA-MB-231, MCF-7 and MCF-12A cells after 24 h exposure. by Barend Andre Stander (108706)

    Published 2013
    “…<p>Relative mean fluorescence intensity of DCF (FL1) (A) hydroethidine (FL3) (B) in MCF-7, MDA-MB-231 and MCF-12A cells exposed to ESE-16 (200 nM). …”
  11. 14491
  12. 14492
  13. 14493
  14. 14494

    A novel SNP of <i>MYO1A</i> gene associated with heat-tolerance in Chinese cattle by Yanhong Cao (428443)

    Published 2022
    “…Further analysis showed that frequency of wild allele A decreased gradually from northern cattle to southern cattle, whereas frequency of mutant type allele G showed the opposite pattern, which was consistent with the distribution of various climatic conditions of China. …”
  15. 14495

    Integrin and RNF31 binding to SHARPIN are mutually exclusive. by Nicola De Franceschi (4518478)

    Published 2015
    “…(B) Co-immunoprecipitation of endogenous SHARPIN, RNF31 and ITGAL from Jurkat cells (a GFP antibody was used as negative control). (C) Pull-down of GFP-SHARPIN from HEK293 cells demonstrated that cells in suspension show decreased RNF31-SHARPIN interaction compared to adherent cells (n = 4). …”
  16. 14496
  17. 14497
  18. 14498
  19. 14499
  20. 14500

    ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alo... by Rafael de Montier P. Barroso (10366820)

    Published 2021
    “…After treatment, best-corrected visual acuity was significantly (p<0.05) improved at all follow-up visits in the group receiving intravitreal injection alone, at all but week 4 in the ETDRS group, and at all but weeks 4 and 8 for the PASCAL group. A significant decrease in central subfield macular thickness was observed in the PASCAL group at weeks 4, 8, and 48; only at week 48 in the intravitreal injection group; and never in the ETDRS group. …”